Harvard Infectious Diseases in Adults 2021

Highlights of the 2021 Program

Expanded Case-Based and Problem-Solving Education 

The 2021 program features an expanded range of interactive, case-based and problem-solving education. The formats are engaging and attendees are encouraged to pose questions of our national experts in Q and A sessions following the lectures and the workshops.

Treating Highly Resistant Infections, including:

• MRSA and VISA (vancomycin-intermediate Staph aureus)


• Extended spectrum beta-lactamase (ESBL)-producing gram negative rods


• Carbapenemase-producing gram negative rods, including the NDM-1 metallo-beta-lactamase-producing organisms


• Vancomycin-resistant enterococci (VRE)


• Aspergillus and  non-aspergillus mold infections


• Candida auris


• Nontuberculous mycobacteria (NTM)

Common Infectious Diseases: Updates in Prevention, Diagnosis, and Treatment

Updates to keep you current on new strategies, state-of-the-art practices, and the most recent guidelines to address:

• Infections in the expanding populations of immunocompromised hosts


• Infections in persons with substance use disorders


• Infections of travelers and foreign-born persons


• Systemic fungal infections


• Native and device-related orthopedic infections


• Central nervous system (CNS) infections


• Ear, nose and throat (ENT) and eye infections


• Bronchiectasis and pneumonia


• HIV and its infectious and noninfectious complications


• PEP (Post-Exposure Prophylaxis) and PrEP (Pre-Exposure Prophylaxis) to prevent HIV infection


• Sexually transmitted infections


• Hepatitis B and C infections


• Tick- and mosquito-borne infections


• Vaccines and vaccine-preventable infections


• Clostridioides difficile infection

Challenging, Rare, and Emerging Infectious Diseases

Comprehensive updates on:

• COVID-19


• EEE, Zika, Ebola, Middle Eastern Respiratory Syndrome (MERS), and other emerging infectious diseases


• Re-emergence of vaccine-preventable diseases


• Pulmonary and extrapulmonary non-tuberculous (“atypical”) mycobacteria, including Mycobacterium abscessus


• Global infectious diseases of clinical importance

Clinical Decision-Making

Hear directly from world-renowned specialists and master clinicians on their approach and decision-making criteria for:

• Selecting the best antimicrobial and duration of treatment


• Rapid detection and empiric treatment of the life-threatening infectious diseases


• Inpatient or outpatient treatment, and the outpatient antibiotic transition: IV or oral?


• Optimizing empiric antimicrobial therapy: what to start, when to narrow or stop

Our multidisciplinary talks and workshops incorporate safety, quality, and practice improvement in infectious diseases, including:

• Antimicrobial stewardship to prevent resistance and reduce cost


• Infection control, including biothreats


• Early inpatient ID consultations to improve outcomes


• Strategies for management of infection in persons who inject drugs (PWID)

Optimized for Remote Education

The 2021 program has been enhanced for distance learning. In addition to being live streamed, all sessions will be recorded and made available to participants for online viewing for 30 days after the end of the course.